Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the H.C. Wainwright & Co. 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Dwight Egan will present on the company’s progress and upcoming Co-Dx PCR Home Diagnostic Platform. The presentation is scheduled for September 13 at 8:30 AM ET, accessible for registered institutional investors. One-on-one meetings with H.C. Wainwright representatives will also be available.
SALT LAKE CITY, Aug. 31, 2022 /PRNewswire/ -- Co-Diagnostics (Nasdaq: CODX) will showcase its innovative molecular diagnostics at Medical Fair Asia 2022 from August 31 to September 2 in Singapore. This premier medical trade fair is expected to attract over 14,000 visitors from 70 countries, offering Co-Dx an opportunity to strengthen its distributor outreach and connect with international customers. Attendees can learn more about Co-Diagnostics’ products, including its point-of-care PCR diagnostics, at Booth #2G01.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is set to sponsor, present, and host a booth at the 14th Annual Next Generation Dx Summit from August 22-24 in Washington, D.C.. The summit focuses on advancements in point-of-care, infectious disease, and liquid biopsy diagnostics. CEO Dwight Egan will present the upcoming Co-Dx PCR Home platform on August 22 at 12:15 PM ET. In-person attendees can visit the Company at Booth #206. For more details on the summit, visit Next Generation Dx.
Co-Diagnostics, Inc. (NASDAQ: CODX) released its second quarter 2022 financial results, reporting a revenue decline to $5.0 million from $27.4 million year-over-year, primarily due to decreased demand for its Logix Smart™ COVID-19 Test. The company faced an operating loss of $4.1 million, contrasting with a prior year operating income of $11.8 million. Net loss registered at $2.7 million, or $0.08 per share. Despite these challenges, Co-Diagnostics continues to progress on the Co-Dx PCR Home platform and expand its product offerings, including tests for monkeypox.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Yale School of Public Health SalivaDirect™ Conference on July 28-29 in Chicago. The conference focuses on promoting saliva-based testing for infectious diseases. CEO Dwight Egan and Chairman of the Scientific Advisory Board Dr. Carl Wittwer will present on the topic "The Opportunity for A New Global Response To Infectious Disease" on July 29th at 3:00 PM CT. Co-Diagnostics specializes in molecular diagnostics, developing advanced technologies for testing infectious diseases and genetic markers.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced a global expansion of its OEM agreement with Bio Molecular Systems (BMS) during its update at AACC. This expanded agreement increases Co-Dx's approved sales territories to 193 countries, building on existing sales in over 50 countries. BMS, known for its expertise in PCR technology, manufactures the Co-Dx Box™, enhancing the user experience of Co-Diagnostics' molecular assays. CEO Dwight Egan expressed optimism about the growth opportunities this collaboration presents for expanding the reach of their affordable and high-quality molecular testing tools.
Co-Diagnostics, Inc. (Nasdaq: CODX) will showcase its diagnostics products at the AACC Annual Scientific Meeting & Clinical Lab Expo from July 24-28 in Chicago, IL. The Company invites distributors and customers for a global update on July 26 at 11 am CT in room S103A. CEO Dwight Egan will present on the Co-Dx PCR Home testing platform at 2 pm CT on July 26. Co-Dx has sold over 34 million PCR tests across more than 50 countries. The Co-Dx PCR Home testing platform is under FDA review and not yet available for sale.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced the shipment of testing reagents for monkeypox virus to an international distributor amidst a global outbreak. As of July 7, 2022, over 6,000 monkeypox cases have been reported across 59 countries, according to the World Health Organization. The reagents were developed quickly to meet urgent regional demands. CEO Dwight Egan emphasized the importance of their PCR-based testing products for effective disease detection, underscoring the company's commitment to high-quality, affordable diagnostics worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its presentation at the 29th International Biodetection Technologies Conference, held virtually on June 28-29, 2022. CEO Dwight Egan will discuss the upcoming PCR Home testing platform during the Point-of-Care Diagnostics agenda on June 29 at 12:30 pm ET. This conference focuses on the latest innovations in the detection and identification of biological threats. An archived version of the presentation will be available on the company's website post-conference.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that key executives will participate in the Sidoti Summer Small Cap Virtual Investor Conference on June 15-16, 2022. CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will present and hold one-on-one meetings with investors. The presentation starts at 3:15 p.m. EDT on June 15 and can be accessed via the company's website. Co-Diagnostics specializes in molecular diagnostics, focusing on developing tests that analyze nucleic acid molecules for various applications, including infectious diseases.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
